Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017 (2017), Article ID 2095682, 6 pages
https://doi.org/10.1155/2017/2095682
Research Article

Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic Syndrome

Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China

Correspondence should be addressed to Xiaomei Hu; moc.361@2_iemoaixuh

Received 3 May 2017; Revised 21 August 2017; Accepted 10 September 2017; Published 16 November 2017

Academic Editor: I-Min Liu

Copyright © 2017 Qianzhe Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. To establish the clinical safe and effective methods of arsenic-containing compound-Qinghuang Powder (compound-QHP) in the treatment of myelodysplastic syndrome (MDS). Methods. 200 patients with MDS were treated with compound-QHP (daily dose of 0.1 g realgar). The blood arsenic concentrations (BACs) were detected by atomic fluorescence spectrophotometry (HF-AFS). After treatment for 1 month, the patients were randomly divided into group A and group B when the BACs were less than 20 μg/L. Daily dose of realgar was maintained in group A and it was increased to that when the BACs were more than 20 μg/L in group B. The BAC and clinical efficacy and safety in two groups were compared at the end of the treatment with compound-QHP. Results. The average BAC of group B was significantly higher than that of group A (). The rates of hematology improvement and reduced transfusion were significantly higher in group B than in group A (). The HGB, ANC, and PLT significantly increased in group B after treatment (). Conclusions. Monitoring the BAC and adjusting the daily dose of realgar to increase the effective BAC and then improving efficacy without increasing the clinical toxicity are the clinical safe and effective methods in the treatment of MDS.